BC Cancer Vancouver Centre, University of British Columbia, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.
Curr Oncol. 2022 Jul 7;29(7):4748-4767. doi: 10.3390/curroncol29070377.
Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment options for metastatic TNBC, including recent advances with the use of immunotherapy, PARP inhibitors and antibody-drug conjugates. This review also explores new agents and novel combinations arising in the field for the treatment of advanced TNBC.
三阴性乳腺癌（TNBC）预后较差，仍然是治疗最具挑战性的乳腺癌亚型。这在很大程度上与该疾病的异质性和缺乏可靠的肿瘤靶点有关。在这篇综述中，我们讨论了转移性 TNBC 的当前标准治疗选择，包括免疫疗法、PARP 抑制剂和抗体药物偶联物的最新进展。本文还探讨了在晚期 TNBC 治疗领域出现的新药物和新联合治疗方案。
